(-0.02%) 5 477.25 points
(0.07%) 38 844 points
(-0.06%) 19 909 points
(-0.17%) $80.19
(0.93%) $2.81
(0.24%) $2 334.50
(0.29%) $29.48
(0.60%) $976.70
(0.13%) $0.933
(0.25%) $10.68
(0.09%) $0.788
(0.31%) $88.73
Live Chart Being Loaded With Signals
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells...
Stats | |
---|---|
本日の出来高 | 94 426 |
平均出来高 | 262 332 |
時価総額 | 9.57M |
EPS | $-0.240 ( Q2 | 2023-08-10 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.225 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0390 (10.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-23 | Zabrowksi Dan | Sell | 100 000 | Stock Option (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 146 383 | Common Stock |
2023-08-23 | Wertheimer Samuel P | Sell | 100 000 | Stock Option (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 12 383 | Warrants (right to buy) |
2023-08-23 | Wertheimer Samuel P | Sell | 1 845 | Warrants (right to buy) |
INSIDER POWER |
---|
-62.55 |
Last 97 transactions |
Buy: 2 466 920 | Sell: 6 182 886 |
ボリューム 相関
Apexigen, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Apexigen, Inc. 相関 - 通貨/商品
Apexigen, Inc. 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.590 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-1.590 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.931 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.36 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Apexigen, Inc.
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。